Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Opioid peptides are crucial for pain management and understanding neurological pathways.
• Developing selective opioid receptor ligands is key to minimizing side effects.
• Cyclic peptides offer unique structural properties for drug design.

Purpose of the Study:

• To synthesize and evaluate novel side chain-to-side chain cyclized opioid peptide analogs.
• To investigate the impact of macrocyclic ring size on opioid receptor binding affinity and selectivity.
• To explore structure-activity relationships for MOP, DOP, and KOP receptor interactions.

Main Methods:

• Solid-phase synthesis of cyclic peptide analogs with varying ring sizes and amino acid substitutions.
• In vitro biological evaluation using calcium mobilization assays in CHO cells expressing human opioid receptors.
• Binding affinity studies for MOP, DOP, and KOP opioid receptors.

Main Results:

• Smaller macrocyclic rings generally increased MOP receptor selectivity.
• The Dap-containing analog exhibited complete MOP receptor selectivity with subnanomolar affinity.
• A truncated analog (Tyr-c[D-Lys-Phe-Asp]NH2) also showed potent and selective MOP receptor antagonism.
• Good correlation observed between receptor binding and functional assay results.

Conclusions:

• Macrocyclic ring size is a critical determinant of opioid receptor selectivity.
• Novel cyclic opioid peptide analogs, particularly the Dap and truncated Lys analogs, represent promising selective MOP receptor ligands.
• Further research into these analogs could lead to improved pain therapeutics with reduced side effects.